Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...